Jimlig 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections caused by susceptible fungi, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the fungal cytochrome P450 enzyme 14α-demethylase, thereby disrupting ergosterol synthesis, an essential component of the fungal cell membrane. This disruption leads to increased membrane permeability and ultimately fungal cell death. Jimlig 200 Capsule is administered orally and is well-absorbed when taken with food, enhancing bioavailability. The dosage regimen varies depending on the type and severity of infection, and treatment duration should be guided by clinical response and microbiological findings. Caution is advised in patients with hepatic impairment, congestive heart failure, or those receiving concomitant medications metabolized by the cytochrome P450 system, due to potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Jimlig 200 Capsule should be used under medical supervision to ensure safe and effective antifungal treatment.